IL‐4/IL‐13 pathway in nasal type 2 inflammation: The central role and targeted therapy
Eye & ENT Research · 2024
DOI: 10.1002/eer3.5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Eye & ENT Research, 2024. Verfasst von Zhiqiu Zhu und 2 weiteren Autor:innen. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Type 2 dominant inflammation in nasal mucosa is the key underlying pathophysiological mechanism of allergic rhinitis (AR) and most presentations of chronic rhinosinusitis with nasal polyps (CRSwNP). Interleukin‐4 (IL‐4) and IL‐13 share common receptor subunits and signaling molecules, which lead to various pathological changes in different cells, playing key roles in the pathogenesis of nasal type 2 inflammation. Numerous clinical trials have shown that biologics targeting key molecules of the IL‐4/IL‐13 pathway, especially IL‐4 receptor alpha, can treat CRSwNP and AR with high efficacy, and are generally well tolerated. Several biologics have been approved for the treatment of difficult‐to‐control CRSwNP, while others also show promising results. Here, we review the IL‐4/IL‐13 pathway, its role in nasal type 2 inflammation, and current targeted therapies related to the IL‐4/IL‐13 pathway, with a focus on AR and CRSwNP.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Zhu, Z., Zhao, C., & Wang, M. (2024). IL‐4/IL‐13 pathway in nasal type 2 inflammation: The central role and targeted therapy. Eye & ENT Research. https://doi.org/10.1002/eer3.5
Vancouver
Zhu Z, Zhao C, Wang M. IL‐4/IL‐13 pathway in nasal type 2 inflammation: The central role and targeted therapy. Eye & ENT Research. 2024. doi:10.1002/eer3.5
BibTeX
@article{Zhu2024,
author = {Zhu, Zhiqiu and Zhao, Chaoran and Wang, Ming},
title = {IL‐4/IL‐13 pathway in nasal type 2 inflammation: The central role and targeted therapy},
journal = {Eye & ENT Research},
year = {2024},
doi = {10.1002/eer3.5}
}
EUVIMED